Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 6,441 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin to Skin Clear all
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.

NCT02264288
View directory record Official record
Conditions
Peripheral Arterial Disease, Diabetic Foot
Interventions
PDA-002, Placebo
Biological · Other
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
45
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 28, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea

NCT04153188
View directory record Official record
Conditions
Erythematotelangiectatic Rosacea
Interventions
The Vbeam® Prima System, Oxymetazoline HCL 1% Cream
Device · Drug
Lead sponsor
Candela Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Charlotte, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 28, 2026, 5:10 AM EDT
Completed Not applicable Interventional

Brief Cognitive Behavioral Therapy to Treat Itch Rumination "Itch CBT" in Eczema

NCT04486742
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Itch CBT
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
8 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 28, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

NCT00006368
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Lymphoma, Melanoma (Skin), Neoplastic Syndrome
Interventions
yttrium Y 90-edotreotide
Radiation
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 28, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation

NCT00792688
View directory record Official record
Conditions
Wounds
Interventions
GLYC-101 Gel (0.1%), GLYC-101 Gel (1.0%), GLYC-101 Placebo
Drug
Lead sponsor
TR Therapeutics
Industry
Eligibility
25 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 28, 2026, 5:10 AM EDT
Completed Not applicable Interventional Results available

Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies

NCT01142661
View directory record Official record
Conditions
Breast Cancer
Interventions
Eribulin Mesylate
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
5
States / cities
La Verne, California • Nyack, New York • Raleigh, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 28, 2026, 5:10 AM EDT
Not listed Not applicable Interventional

Trial Comparing SOC +Skin IQ MCM vs SOC for Pressure Ulcer (PU)

NCT02363842
View directory record Official record
Conditions
Pressure Ulcer
Interventions
Skin IQ™ MCM Coverlet, Pressure redistribution surface
Device · Other
Lead sponsor
Arjohuntleigh
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Oklahoma City, Oklahoma • Dallas, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2015 · Synced Oct 28, 2026, 5:10 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation

NCT00656474
View directory record Official record
Conditions
Wounds
Interventions
Placebo gel, GLYC-101 gel (1.0 %)
Drug
Lead sponsor
TR Therapeutics
Industry
Eligibility
25 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 28, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Onabotulinum Toxin Type A and Abobotulinum Toxin Type A Crow's Feet Rhytid Study

NCT01529788
View directory record Official record
Conditions
Intrinsic Aging of Skin, Solar Elastosis
Interventions
Right lateral orbital injection of Botox Cosmetic or Dysport, Left lateral orbital injection of Botox Cosmetic or Dysport
Drug
Lead sponsor
The Maas Clinic
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Oct 28, 2026, 5:10 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus

NCT06032923
View directory record Official record
Conditions
Systemic Lupus Erythematosus (Sle)
Interventions
Nicotinamide Riboside
Dietary Supplement
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 120 Years · Female only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 28, 2026, 5:10 AM EDT
Completed Phase 3 Interventional

To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)

NCT02601703
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tacrolimus Ointment 0.1%, Protopic® ointment, 0.1%, Placebo of Tacrolimus Ointment
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
18 Years and older
Enrollment
1,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
60
States / cities
Tempe, Arizona • Anaheim, California • Bell Gardens, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 28, 2026, 5:10 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Study to Determine if Tissue Scored With a Scalpel Results in Any Noticeable Marks

NCT00367042
View directory record Official record
Conditions
Skin Cancer
Interventions
Scalpel for tissue scoring, Surgical marker for tissue marking
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 28, 2026, 5:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Understanding Barriers to Initiation and Adherence to Endocrine Therapy in Young Breast Cancer Survivors of Diverse Backgrounds

NCT03447886
View directory record Official record
Conditions
Breast Cancer
Interventions
Phone interview
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 28, 2026, 5:10 AM EDT
Completed Phase 2 Interventional

Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2

NCT00005635
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, paclitaxel
Biological · Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Oct 28, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis

NCT03347110
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
11
States / cities
Lexington, Kentucky • Hagerstown, Maryland • Lansing, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 28, 2026, 5:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma

NCT01740297
View directory record Official record
Conditions
Melanoma
Interventions
Talimogene laherparepvec, Ipilimumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
32
States / cities
Tucson, Arizona • Beverly Hills, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 28, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis

NCT04230213
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
PF-06410293, adalimumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Bowling Green, Kentucky • Duncansville, Pennsylvania • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Oct 28, 2026, 5:10 AM EDT
Recruiting Phase 2 Interventional

Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)

NCT07062588
View directory record Official record
Conditions
Osteogenesis Imperfecta (OI)
Interventions
AGA2115, Placebo
Drug · Other
Lead sponsor
Angitia Incorporated Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Phoenix, Arizona • New Haven, Connecticut • Wilmington, Delaware + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 28, 2026, 5:10 AM EDT
Completed Not applicable Interventional

Heart Health After Cancer Treatment (HEART-ACT)

NCT06055803
View directory record Official record
Conditions
Breast Cancer
Interventions
Intake Session, Individual Sessions, Group Sessions, Graduation, Exercise
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 28, 2026, 5:10 AM EDT
Terminated Phase 3 Interventional

Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

NCT04869943
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Enobosarm, Exemestane
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
34
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2024 · Synced Oct 28, 2026, 5:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Collaborative Connected Health (CCH) for PCORI

NCT02358135
View directory record Official record
Conditions
Psoriasis
Interventions
Collaborative Connected health, (CCH), Control
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 28, 2026, 5:10 AM EDT
Completed Phase 2 Interventional

A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence

NCT04844840
View directory record Official record
Conditions
Keloid
Interventions
STP705, Placebo
Drug · Other
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Scottsdale, Arizona • Aventura, Florida • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 28, 2026, 5:10 AM EDT
Terminated Phase 2 Interventional

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

NCT05268289
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Iptacopan (part 1), Iptacopan (part 2), Placebo + standard of care, Iptacopan + placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
16
States / cities
Los Angeles, California • San Bernardino, California • Sylmar, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 28, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria

NCT03436797
View directory record Official record
Conditions
Chronic Urticaria
Interventions
AK002
Drug
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Edgewater, Florida • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 28, 2026, 5:10 AM EDT